[go: up one dir, main page]

EA200801287A1 - Пиримидиновые производные для лечения аномального клеточного роста - Google Patents

Пиримидиновые производные для лечения аномального клеточного роста

Info

Publication number
EA200801287A1
EA200801287A1 EA200801287A EA200801287A EA200801287A1 EA 200801287 A1 EA200801287 A1 EA 200801287A1 EA 200801287 A EA200801287 A EA 200801287A EA 200801287 A EA200801287 A EA 200801287A EA 200801287 A1 EA200801287 A1 EA 200801287A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
cell growth
pyrimidine derivatives
anomalous cell
mammals
Prior art date
Application number
EA200801287A
Other languages
English (en)
Other versions
EA014551B1 (ru
Inventor
Джоэль Томас Эркари
Самит Кумар Бхаттачарья
Артур Дуглас Бросиус
Майкл Джозеф Луццио
Кендра Луиз Нельсон
Гонгхуа Пан
мл. Саутерс Джеймс Альфред
Донн Грегори Уишка
Джун Ксьяо
Original Assignee
Пфайзер Продактс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Продактс, Инк. filed Critical Пфайзер Продактс, Инк.
Publication of EA200801287A1 publication Critical patent/EA200801287A1/ru
Publication of EA014551B1 publication Critical patent/EA014551B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyridine Compounds (AREA)

Abstract

Настоящее изобретение относится к соединению формулы (I) или его фармацевтически приемлемой соли, где Аr представляет собой группу (III). Такие пиримидиновые производные полезны в лечении аномального клеточного роста, такого как рак, у млекопитающих. Это изобретение также относится к способу применения таких соединений в лечении аномального клеточного роста у млекопитающих, в особенности людей, и к фармацевтическим композициям, содержащим такие соединения.
EA200801287A 2005-12-21 2006-12-11 Пиримидиновые производные для лечения аномального клеточного роста EA014551B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75270805P 2005-12-21 2005-12-21
PCT/IB2006/003655 WO2007072158A2 (en) 2005-12-21 2006-12-11 Pyrimidine derivatives for the treatment of abnormal cell growth

Publications (2)

Publication Number Publication Date
EA200801287A1 true EA200801287A1 (ru) 2008-10-30
EA014551B1 EA014551B1 (ru) 2010-12-30

Family

ID=38038639

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200801287A EA014551B1 (ru) 2005-12-21 2006-12-11 Пиримидиновые производные для лечения аномального клеточного роста

Country Status (30)

Country Link
US (1) US7820648B2 (ru)
EP (1) EP1966207A2 (ru)
JP (1) JP4332590B2 (ru)
KR (1) KR101060051B1 (ru)
CN (1) CN101346380B (ru)
AP (1) AP2008004488A0 (ru)
AR (1) AR058399A1 (ru)
AU (1) AU2006327871A1 (ru)
BR (1) BRPI0620324A2 (ru)
CA (1) CA2634646C (ru)
CR (1) CR10095A (ru)
DO (1) DOP2006000289A (ru)
EA (1) EA014551B1 (ru)
EC (1) ECSP088563A (ru)
GT (1) GT200600517A (ru)
HN (1) HN2006042221A (ru)
IL (1) IL191555A0 (ru)
MA (1) MA30075B1 (ru)
ME (1) MEP0908A (ru)
NL (1) NL2000375C2 (ru)
NO (1) NO20082338L (ru)
PE (1) PE20071138A1 (ru)
RS (1) RS20080272A (ru)
SV (1) SV2008002969A (ru)
TN (1) TNSN08270A1 (ru)
TW (1) TW200736258A (ru)
UA (1) UA89123C2 (ru)
UY (1) UY30051A1 (ru)
WO (1) WO2007072158A2 (ru)
ZA (1) ZA200804488B (ru)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4886511B2 (ja) 2003-07-30 2012-02-29 ライジェル ファーマシューティカルズ, インコーポレイテッド 2,4−ピリミジンジアミン化合物による自己免疫疾患の治療または予防方法
US20070032514A1 (en) * 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
CA2654670A1 (en) * 2006-07-06 2008-01-10 Boehringer Ingelheim International Gmbh New compounds
TWI432427B (zh) * 2006-10-23 2014-04-01 Cephalon Inc 作為ALK及c-MET抑制劑之2,4-二胺基嘧啶之融合雙環衍生物
JP4782239B2 (ja) 2007-04-18 2011-09-28 ファイザー・プロダクツ・インク 異常細胞増殖治療のためのスルホニルアミド誘導体
BRPI0814432A2 (pt) 2007-07-17 2017-05-09 Rigel Pharmaceuticals Inc pirimidinadiaminas substituídas por amina cíclica como inibidores de pkc
US8461147B2 (en) * 2007-12-03 2013-06-11 Boehringer Ingelheim International Gmbh Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
UY31714A (es) * 2008-03-20 2009-11-10 Boehringer Ingelheim Int Preparación selectiva de pirimidinas sustituidas
CA2718858A1 (en) * 2008-03-20 2009-09-24 Boehringer Ingelheim International Gmbh Selective synthesis of substituted pyrimidines
WO2009153589A1 (en) 2008-06-17 2009-12-23 Astrazeneca Ab Pyridine compounds
EP2161259A1 (de) 2008-09-03 2010-03-10 Bayer CropScience AG 4-Halogenalkylsubstituierte Diaminopyrimidine als Fungizide
US20110071158A1 (en) * 2009-03-18 2011-03-24 Boehringer Ingelheim International Gmbh New compounds
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
WO2011018517A1 (en) 2009-08-14 2011-02-17 Boehringer Ingelheim International Gmbh Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US8466155B2 (en) * 2009-10-02 2013-06-18 Boehringer Ingelheim International Gmbh Pyrimidines
TWI513694B (zh) 2010-05-11 2015-12-21 Amgen Inc 抑制間變性淋巴瘤激酶的嘧啶化合物
RU2528386C2 (ru) 2010-05-21 2014-09-20 Кемилиа Аб Новые производные пиримидина
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
PT2646448T (pt) 2010-11-29 2017-10-04 Osi Pharmaceuticals Llc Inibidores macrocíclicos de cinases
CA2830129C (en) 2011-03-24 2016-07-19 Chemilia Ab Novel pyrimidine derivatives
BR112014013178A2 (pt) 2011-12-09 2017-06-13 Chiesi Farm Spa composto, composição farmacêutica e uso de um composto
CN104169272A (zh) 2011-12-23 2014-11-26 赛尔佐姆有限公司 作为激酶抑制剂的嘧啶-2,4-二胺衍生物
CN103655577A (zh) * 2012-09-20 2014-03-26 杨育新 一类治疗创伤性脑损伤疾病的化合物及其用途
CN103664957A (zh) * 2012-09-25 2014-03-26 杨子娇 一类治疗房角狭窄的化合物及其用途
CN105130907B (zh) * 2015-07-29 2018-10-16 沈阳药科大学 嘧啶类化合物及其用途
ES2846833T3 (es) 2016-07-18 2021-07-29 Janssen Pharmaceutica Nv Ligandos de obtención de imágenes de tau por PET
WO2020023851A1 (en) * 2018-07-26 2020-01-30 Yale University Bifunctional substitued pyrimidines as modulators of fak proteolyse
AU2022205713A1 (en) * 2021-01-07 2023-07-27 Ontario Institute For Cancer Research (Oicr) Thienyl and cycloalkyl aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereof
JP2024502175A (ja) * 2021-01-07 2024-01-17 オンタリオ・インスティテュート・フォー・キャンサー・リサーチ(オーアイシーアール) Nuakキナーゼの阻害剤としてのイソインドリノンアミノピリミジン化合物、その組成物及び使用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB0004887D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
WO2003095448A1 (en) 2002-05-06 2003-11-20 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
US7504410B2 (en) * 2002-11-28 2009-03-17 Schering Aktiengesellschaft Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
JP2006515014A (ja) * 2003-01-30 2006-05-18 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド PKC−θのインヒビターとして有用な2,4−ジアミノピリミジン誘導体
JP2007537238A (ja) * 2004-05-14 2007-12-20 ファイザー・プロダクツ・インク 異常細胞増殖の治療のためのピリミジン誘導体
MXPA06011890A (es) * 2004-05-14 2006-12-14 Pfizer Prod Inc Derivados de pirimidina para tratar el crecimiento celular anomalo.

Also Published As

Publication number Publication date
DOP2006000289A (es) 2007-07-31
MEP0908A (xx) 2010-02-10
WO2007072158A2 (en) 2007-06-28
NO20082338L (no) 2008-06-25
AR058399A1 (es) 2008-01-30
NL2000375C2 (nl) 2008-01-03
CA2634646A1 (en) 2007-06-28
NL2000375A1 (nl) 2007-06-25
US20080234303A1 (en) 2008-09-25
ZA200804488B (en) 2009-05-27
US7820648B2 (en) 2010-10-26
TW200736258A (en) 2007-10-01
KR101060051B1 (ko) 2011-08-29
WO2007072158A8 (en) 2008-08-14
KR20080077026A (ko) 2008-08-20
PE20071138A1 (es) 2007-12-29
CN101346380A (zh) 2009-01-14
JP4332590B2 (ja) 2009-09-16
MA30075B1 (fr) 2008-12-01
EA014551B1 (ru) 2010-12-30
CR10095A (es) 2008-07-17
TNSN08270A1 (fr) 2009-10-30
ECSP088563A (es) 2008-07-30
SV2008002969A (es) 2010-08-17
JP2009520807A (ja) 2009-05-28
CA2634646C (en) 2012-04-10
RS20080272A (sr) 2009-07-15
UY30051A1 (es) 2007-07-31
HN2006042221A (es) 2010-01-18
CN101346380B (zh) 2012-02-29
UA89123C2 (ru) 2009-12-25
IL191555A0 (en) 2008-12-29
AP2008004488A0 (en) 2008-06-30
WO2007072158A3 (en) 2007-12-27
EP1966207A2 (en) 2008-09-10
GT200600517A (es) 2007-09-13
BRPI0620324A2 (pt) 2011-11-08
AU2006327871A1 (en) 2007-06-28

Similar Documents

Publication Publication Date Title
EA200801287A1 (ru) Пиримидиновые производные для лечения аномального клеточного роста
TW200607801A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
TW200612949A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
EA200971104A1 (ru) Производные бензимидазола
TNSN06074A1 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
MXPA06013164A (es) Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal.
MX2009011090A (es) Derivados de sulfonil amida para el tratamiento del crecimiento celular anormal.
EA200701808A1 (ru) Производные тетрагидроиндолона и тетрагидроиндазолона
DE602005004286D1 (de) 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyridoä2,3-düpyrimidinderivate und verwandte verbindungen zur behandlung von krebs
MXPA05012025A (es) Imidazo y tiazolopiridinas como inhibidores de cinasa jak3.
WO2011027249A3 (en) Benzimidazole derivatives
EA201170617A1 (ru) Пиразолиламинопиридины в качестве ингибиторов fak
SE0400284D0 (sv) Novel compounds
EA201170722A1 (ru) Лактамы в качестве ингибиторов бета-секретазы
MXPA05010440A (es) Amidas del acido isoquinolina-5-sulfonico como inhibidores de la akt (proteina quinasa b).
EA200601796A1 (ru) Пиримидиновые производные для лечения аномального клеточного роста
MX2007013624A (es) Inhibidores de proteina cinasa.
EA200702375A1 (ru) Производные мочевины, способы их получения и применения
WO2007017728A3 (en) Novel heterocyclic compounds
ATE543803T1 (de) 3-ä2-(3-azylamino-2-oxo-2h-pyridin-1- yl)acetylaminoü-4-oxopentansäurederivate und deren verwendung als caspase-inhibitoren
WO2007076087A3 (en) 3-aryl-substituted quinazolones, and uses thereof
TW200505869A (en) Thiophenylaminoimidazolines
MY153733A (en) Novel quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same
MX2024006176A (es) Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno.
EA200970496A1 (ru) Соединения 2-алкилиндазола для лечения некоторых расстройств цнс

Legal Events

Date Code Title Description
TK4A Corrections in published eurasian patents
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU